

## SUPPLEMENTARY DATA

**Supplementary Table S1** Summary of grade 5 adverse events

Grade 5 adverse event	Age at start of bevacizumab, y	Date of first bevacizumab dose	Date of last bevacizumab dose	Date of adverse event onset	Date of death	Relationship to bevacizumab	Suspected cause of death	Additional information
Febrile neutropenia	61	24 Feb 2014	1 Sep 2014	14 Dec 2014	19 Dec 2014	Unrelated	Neutropenic sepsis	Ovarian cancer recorded as secondary cause of death
Cardiac arrest	55	21 Nov 2013	13 Nov 2014	29 Apr 2015	29 Apr 2015	Unrelated	Septicemia	
Gastrointestinal perforation	60	8 Feb 2013	27 Sep 2013	1 Oct 2013	3 Oct 2013	Probable	Gastrointestinal perforation	Patient had a mucinous tumor, received oxaliplatin and capecitabine chemotherapy, and had a long-standing history of ulcerative colitis
Abdominal pain (bowel obstruction secondary to disease progression)	75	11 Nov 2014	24 Nov 2015	29 Nov 2015	1 Dec 2015	Unrelated	Ovarian cancer	Laparotomy 30 Nov 2015
Pneumonia developed from aspiration	73	14 May 2014	28 Aug 2014	7 Sep 2014	12 Oct 2014	Unrelated	Ovarian cancer, global transient amnesia, CVA	CVA admission 31 Aug 2014

---

Leptomeningeal disease	57	24 Dec 2014	21 May 2015	3 Jul 2015	10 Jul 2015	Unrelated	Leptomeningeal disease	
Pneumonia	46	9 Nov 2012	8 Nov 2013	14 Sep 2014	14 Sep 2014	Unrelated	Disease progression	Patient received gemcitabine/ carboplatin 5–29 Aug 2014

---

CVA, cerebrovascular accident.